weight loss glp-1 agonists Comparing Ozempic, Wegovy and Other Drugs Part 2 of a 3-Part

It has shown significant promise as an effective intervention against type 2 diabetes (T2D) and excessive body weight, resulting in the United States Food and Drug Administration (FDA) approving its use against both conditions in May 2022 for T2D and November 2023 for obesity

Pawaskar, M., Tuttle, K

This increased risk was confined to women using GLP-1 receptor agonists for diabetes treatment (liraglutide aOR 1.70, 95% CI 1.172.48

Borthwick Diabetes Research Centre, Lister Hospital, Coreys Mill Ln, Stevenage SG1 4AB, UK Tel: +44-1438-285972, Fax: +44-1438-284150, E-mail: [email protected] Copyright 2024 Korean Endocrine Society This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License ( which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited

Slow titration will also help decrease gastrointestinal symptoms that may arise

Gastroenterol Clin N Am